Patents by Inventor Ronnie C. Mease

Ronnie C. Mease has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11021450
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: June 1, 2021
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • Patent number: 10947197
    Abstract: Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: March 16, 2021
    Assignee: The Johns Hopkins University
    Inventors: Hayden T. Ravert, Daniel P. Holt, Ying Chen, Ronnie C. Mease, Hong Fan, Martin G. Pomper, Robert F. Dannals
  • Publication number: 20210040126
    Abstract: PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature are disclosed. Methods of imaging PSMA expressing tumors, or cells and kits also are disclosed.
    Type: Application
    Filed: July 21, 2020
    Publication date: February 11, 2021
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray
  • Patent number: 10857246
    Abstract: Highly potent and selective radionuclide-based imaging and therapy agents targeting carbonic anhydrase IX with minimum non-specific organ uptake are disclosed. Methods of imaging and/or treating carbonic anhydrase IX-expressing cells or tumors also are disclosed.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: December 8, 2020
    Assignee: The Johns Hopkins University
    Inventors: Xing Yang, Il Minn, Steven Rowe, Sangeeta Ray, Ronnie C. Mease, Michael Gorin, Mohamad Allaf, Martin G. Pomper
  • Publication number: 20200360542
    Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
    Type: Application
    Filed: August 4, 2020
    Publication date: November 19, 2020
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray, Ying Chen, Xing Yang
  • Publication number: 20200290982
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific T1-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 17, 2020
    Inventors: Sangeeta Ray, Martin G. Pomper, Thomas J. Meade, Ronnie C. Mease, Ying Chen, Xing Yang, Matthew Rotz
  • Publication number: 20200283412
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: June 15, 2018
    Publication date: September 10, 2020
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • Patent number: 10736974
    Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: August 11, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray, Ying Chen, Xing Yang
  • Publication number: 20200231614
    Abstract: PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.
    Type: Application
    Filed: October 21, 2016
    Publication date: July 23, 2020
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, SANGEETA RAY, MICHAEL ZALUTSKY, GANESAN VAIDYANATHAN
  • Patent number: 10717750
    Abstract: PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature are disclosed. Methods of imaging PSMA expressing tumors, or cells and kits also are disclosed.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: July 21, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray
  • Publication number: 20200216402
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • Patent number: 10683272
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: June 16, 2020
    Assignees: THE JOHNS HOPKINS UNIVERSITY, NORTHWESTERN UNIVERSITY
    Inventors: Sangeeta Ray, Martin G. Pomper, Thomas J. Meade, Ronnie C. Mease, Ying Chen, Xing Yang, Matthew Rotz
  • Publication number: 20200170960
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Application
    Filed: July 8, 2019
    Publication date: June 4, 2020
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Patent number: 10653806
    Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?-, ?-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: May 19, 2020
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Sangeeta Ray, Ronnie C. Mease, Hassan Shallal
  • Publication number: 20200109124
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: December 5, 2019
    Publication date: April 9, 2020
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray, Jonathan Sorger
  • Patent number: 10369113
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 6, 2019
    Assignee: The Johns Hopkins University
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Publication number: 20190225589
    Abstract: Triazole conjugated urea-based and thiourea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used to image cells and tumors that express PSMA. Methods of synthesizing radiofluorinated triazole conjugated urea-based and thiourea-based scaffolds also are disclosed.
    Type: Application
    Filed: August 15, 2016
    Publication date: July 25, 2019
    Inventors: MARTIN G. POMPER, YING CHEN, XING YANG, RONNIE C. MEASE, SANGEETA RAY
  • Publication number: 20190192699
    Abstract: Highly potent and selective radionuclide-based imaging and therapy agents targeting carbonic anhydrase IX with minimum non-specific organ uptake are disclosed. Methods of imaging and/or treating carbonic anhydrase IX-expressing cells or tumors also are disclosed.
    Type: Application
    Filed: May 12, 2017
    Publication date: June 27, 2019
    Inventors: Xing YANG, Il MINN, Steven ROWE, Sangeeta RAY, Ronnie C. MEASE, Michael GORIN, Mohamad ALLAF, Martin G. POMPER
  • Publication number: 20190177275
    Abstract: Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.
    Type: Application
    Filed: June 9, 2017
    Publication date: June 13, 2019
    Inventors: Hayden T. Ravert, Daniel P. Holt, Ying Chen, Ronnie C. Mease, Hong Fan, Martin G. Pomper, Robert F. Dannals
  • Publication number: 20190023722
    Abstract: PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature are disclosed. Methods of imaging PSMA expressing tumors, or cells and kits also are disclosed.
    Type: Application
    Filed: March 14, 2016
    Publication date: January 24, 2019
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, SANGEETA RAY